Home

Home - Support and Resources - Citation

2024. 02NGS

Proteomic and metabolomic features in patients with HCC responding to lenvatinib and anti-PD1 therapy

Zhong-Chen Li, Jie Wang, He-Bin Liu, Yi-Min Zheng, Jian-Hang Huang, Jia-Bin Cai, Lei Zhang, Xin Liu, Ling Du, Xue-Ting Yang, Xiao-Qiang Chai, Ying-Hua Jiang, Zheng-Gang Ren, Jian Zhou, Jia Fan, De-Cai Yu, Hui-Chuan Sun, Cheng Huang, Feng Liu

Full Text

SUMMARY

Combination therapy (lenvatinib/programmed death-1 inhibitor) is effective for treating unresectable hepatocellular carcinoma (uHCC). We reveal that responders have better overall and progression-free survival, as well as high tumor mutation burden and special somatic variants. We analyze the proteome and metabolome of 82 plasma samples from patients with hepatocellular carcinoma (HCC; n = 51) and normal controls (n = 15), revealing that individual differences outweigh treatment differences. Responders exhibit enhanced activity in the alternative/lectin complement pathway and higher levels of lysophosphatidylcholines (LysoPCs), predicting a favorable prognosis. Non-responders are enriched for immunoglobulins, predicting worse outcomes. Compared to normal controls, HCC plasma proteins show acute inflammatory response and platelet activation, while LysoPCs decrease. Combination therapy increases LysoPCs/phosphocholines in responders. Logistic regression/random forest models using metabolomic features achieve good performance in the prediction of responders. Proteomic analysis of cancer tissues unveils molecular features that are associated with side effects in responders receiving combination therapy. In conclusion, our analysis identifies plasma features associated with uHCC responders to combination therapy.

Associated articles

Dynegene Next-Gen Synthesis: Powering Biotech Revolution With Nucleic Acids

Contact Us

Tel: 400-017-9077

Address: Floor 2, Building 5, No. 248 Guanghua Road, Minhang District, Shanghai

Email: zhengyuqing@dynegene.com

Follow Us

Copyright © 2024 Shanghai Dynegene Technologies Co., Ltd.
All rights reserved.   

Website Map I Privacy Policy